34
This audio is auto-generated. Please let us know if you have feedback.
Johnson & Johnson’s landmark approval for Spravato in 2019 busted the door open for a new era of mental health drugs. The esketamine-based depression treatment not only helped validate psychedelics in the psychiatric realm, it’s shown the therapies can reach blockbuster heights as well.
Now,…